Viemed Healthcare, Inc. (VMD) Stock Price & Analysis
Viemed Healthcare, Inc. (VMD) closed at USD 9.99 on Wednesday, October 28, 2026, up 3.20% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 9.68; the Oct 28, 2026 session ranged USD 9.66–10.01 on volume of 204,781 shares. Market capitalization is $380.50M, with a 52-week range of USD 6.05–12.61 (NCM). Source: Nexqual, retrieved October 29, 2026 at 11:03 UTC.
Also available as compact Markdown for AI agents: nexqual.com/VMD.md
Key facts (VMD)
- Last four reported quarters (through Jun 30, 2026): revenue $302M, net income $14.5M (4.8% margin), free cash flow $29.2M (SEC filings).
- Valuation: P/E 26.2x (avg 26.8x at the last 3 fiscal year-ends), EV/EBITDA 9.7x, net cash $3.6M.
- 1 of 80 tracked superinvestors hold VMD (13F, Q2 2026): 0 new, 1 added, 0 reduced, 0 unchanged.
- Insider open-market sales, last ~7 months: 2 Form 4 filings, $347K; 2 not under a Rule 10b5-1 plan ($347K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (2 analysts), mean target USD 12.5 (range 11–14).
- Total return with dividends: 1Y +52.8% vs S&P 500 +13.6%; 5Y +74.3% vs S&P 500 +79.8%.
- Next earnings: 2026-11-04, EPS estimate USD 0.12, revenue estimate $80.8M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (VMD)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $117M | $139M | $183M | $224M | $270M | $302M |
| Gross profit | $73.4M | $84.7M | $113M | $133M | $155M | — |
| Operating income | $11.6M | $8.3M | $14.3M | $17.9M | $22.9M | $22.8M |
| Net income | $9.1M | $6.2M | $10.2M | $11.3M | $14.9M | $14.5M |
| EPS (diluted) | $0.22 | $0.16 | $0.25 | $0.28 | $0.37 | — |
| Free cash flow | $2.8M | $4.8M | $19.1M | $1.3M | $11.9M | $29.2M |
| Gross margin | 62.7% | 61.0% | 61.6% | 59.4% | 57.5% | — |
| Operating margin | 9.9% | 5.9% | 7.8% | 8.0% | 8.5% | 7.5% |
| Net margin | 7.8% | 4.5% | 5.6% | 5.0% | 5.5% | 4.8% |
| Revenue growth | -10.8% | +18.6% | +31.8% | +22.5% | +20.5% | — |
| Cash + short-term investments | $28.4M | $16.9M | $12.8M | $17.5M | $13.5M | — |
| Total debt | $5.8M | $0K | $7.1M | $4.0M | $12.4M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (VMD)
P/E 26.2x · P/S 1.3x · EV/EBITDA 9.7x · EV/Sales 1.3x · P/FCF 13.0x · P/B 2.6x · FCF yield 7.68% · Earnings yield 3.81% · Buyback yield (TTM) 4.82% · Net cash $3.6M · EV $377M
P/E at fiscal year-ends: Dec 2025 20.3x, Dec 2024 29.1x, Dec 2023 30.9x.
Superinvestors (SEC 13F-HR, Q2 2026) (VMD)
1 of 80 tracked investors hold VMD. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 0.01% | $6.1M | Added +1.0% |
Insider sales (SEC Form 4, open-market, last ~7 months) (VMD)
0 of 2 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan | Insider type |
|---|---|---|---|---|---|---|---|
| 2026-06-25 | Frazier William | Chief Medical Officer | 10,000 | $117K | 12% | No | Too little history (no open-market trades in 2023–2025) |
| 2026-06-24 | Smokoff Timothy | Director | 20,000 | $230K | 20.9% | No | Too little history (no open-market trades in 2024) |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.
Analysts (VMD)
Consensus Buy (mean 2.00 on a 1–5 scale), 2 analysts; mean target USD 12.5 (low 11, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-24 | Barrington Research | Initiated | Outperform | $14 |
| 2026-08-06 | Freedom Broker | Downgrade | Buy → Hold | $11 |
Total return (dividends reinvested) (VMD)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +52.8% | +74.3% |
| S&P 500 (SPY) | +13.6% | +79.8% |
| Per year | +53.0% | +11.7% |
| Volatility (annualized) | 39.7% | 41.2% |
| Max drawdown | -30.5% (Jul 2026→Aug 2026) | -49.6% (Apr 2023→Jul 2025) |
VMD major shareholder filing: Schedule 13D/A, Sep 24, 2026
Michael Moore, Moore Faster LLC filed a Schedule 13D/A with the SEC on Sep 24, 2026, reporting up to 5.90% of the class. A Schedule 13D is filed by an owner of more than 5% who may seek to influence the company. Item 4 (Purpose of Transaction), quoted from the filing:
Each of the Reporting Persons holds the Common Shares as reported herein for investment purposes and does not have any specific plans or proposals regarding the Issuer in such Reporting Person's capacity as a holder of Common Shares. Except as set forth below, each of the Reporting Persons does not have any current plans or proposals which relate to, or may result in, any of the matters listed in Items 4(a)-(j) of Schedule 13D. On September 24, 2026, MF LLC entered into a trading plan with Morgan Stanley Smith Barney LLC (the "Trading Plan") intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. Pursuant to the Trading Plan, Morgan Stanley Smith Barney LLC may sell up to 246,000 Common Shares of the Issuer held by MF LLC during the period beginning on the Selling Start Date, as determined under the Trading Plan, which will be no earlier than December 24, 2026, and ending November 30, 2027, subject to predetermined trading conditions established under the Trading Plan. The Trading Plan was adopted at a time when neither Moore nor MF LLC was aware of any material non-public information regarding the Issuer. A copy of the Trading Plan is filed as Exhibit 99.2 to this Amendment No. 3 and is incorporated herein by reference.
Source: SEC EDGAR, Schedule 13D/A filed Sep 24, 2026. Quoted word for word; Nexqual adds no interpretation.
VMD earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Aug 3, 2026 | Quarter ended Jun 30, 2026 | $0.07 | $0.10 | Miss −30.0% | -15.7% |
| May 5, 2026 | Quarter ended Mar 31, 2026 | $0.06 | $0.09 | Miss −33.3% | -10.2% |
| Mar 4, 2026 | Quarter ended Dec 31, 2025 | $0.14 | $0.13 | Beat +7.7% | -6.1% |
| Nov 5, 2025 | Quarter ended Sep 30, 2025 | $0.09 | $0.09 | In line | -4.3% |
| Aug 6, 2025 | — | — | — | — | +10.1% |
| May 7, 2025 | — | — | — | — | -13.2% |
| Mar 10, 2025 | — | — | — | — | +4.0% |
| Nov 6, 2024 | — | — | — | — | +2.3% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
VMD recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Sep 24, 2026 | Schedule 13D/A | Michael Moore, Moore Faster LLC: 5.9% of shares, 5%+ holder that may seek to influence the company (amended) “Each of the Reporting Persons holds the Common Shares as reported herein for investment purposes and does not have any specific plans or proposals regarding the Issuer in such Reporting Person's capacity as a holder of Common Shares. Except as set forth below, each of the…” |
| Aug 20, 2026 | 8-K | Regulation FD disclosure |
| Aug 3, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 3, 2026 | 8-K | Quarterly results |
| Jul 24, 2026 | Schedule 13G/A | Forager Capital Management, LLC, Forager Fund, L.P.: 4.9% of shares, passive 5%+ holder (amended) |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
VMD revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Equipment Sales | $19.0M | 24.3% | +99.4% |
| Service | $6.3M | 8.1% | +6.9% |
| Total revenue | $78.1M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
VMD customer concentration
In the period ended Jun 30, 2026, a single direct customer accounted for 35% of revenue, per the company's 10-Q filed Aug 3, 2026. The company does not name it.
VMD analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $0.12 | $0.13 | -5.1% | $80.8M | 3 |
| Next quarter (ends Dec 2026) | $0.15 | $0.15 | +0.0% | $83.5M | 3 |
| Current fiscal year (ends Dec 2026) | $0.41 | $0.46 | -9.2% | $317.9M | 3 |
| Next fiscal year (ends Dec 2027) | $0.54 | $0.61 | -10.9% | $353.6M | 3 |
VMD options: expected move
Options price a move of about ±28.8% (±$2.88) by Feb 19, 2027, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±8.2% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Feb 19, 2027 | 113 | 68.1% | ±28.8% |
30-day implied volatility 44.9% vs 20.1% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 11:03 UTC)
| Price | USD 9.99 |
|---|---|
| Change | ▲ 3.20% (up) |
| Previous Close | USD 9.68 |
| Open | USD 9.66 |
| Day Range | USD 9.66 – 10.01 |
| 52-Week Range | USD 6.05 – 12.61 |
| Volume | 204,781 shares |
| Market Cap | $380.50M |
| Exchange | NCM |
Technical Analysis (VMD)
Nexqual's technical model rates VMD "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 29, 2026 at 11:03 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 67.91 (neutral) |
| vs SMA50 | Above (USD 9.18) |
| MACD | 0.17 (positive) |
Analyst Ratings (VMD)
Wall Street analysts rate VMD "Buy" based on 2 analysts, with a mean price target of USD 12.5 (range USD 11–14), per Nexqual as of October 29, 2026 at 11:03 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 12.5 |
| High Target | USD 14 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (VMD)
| Next Earnings Date | 2026-11-04 |
|---|---|
| Revenue Estimate | $80.78M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.07 vs est 0.1 ▼ miss |
| 2026-03-31 | USD 0.06 vs est 0.09 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.13 ▲ beat |
| 2025-09-30 | USD 0.09 vs est 0.09 ▲ beat |
Source: Nexqual, October 29, 2026 at 11:03 UTC.
Financials & Fundamentals (VMD)
| Total Revenue | $301.61M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +23.90% |
| Gross Margin | +57.47% |
| Operating Margin | +6.48% |
| Profit Margin | +4.81% |
| ROE | +10.45% |
| Debt / Equity | 0.08 |
| Current Ratio | 1.13 |
| Total Cash | $10.68M |
| Total Debt | $11.60M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $29.24M (9.7% of revenue) |
Source: Nexqual, October 29, 2026 at 11:03 UTC.
Financial Health Score (VMD)
Nexqual rates Viemed Healthcare, Inc.'s overall financial health "Solid" across five dimensions, as of October 29, 2026 at 11:03 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 8% (last 4 quarters to Jun 2026, SEC) |
| Balance Sheet | Strong — $11M cash and investments vs $7M debt (Jun 2026, SEC), net cash |
| Cash Flow | Solid — FCF $29M (last 4 quarters to Jun 2026, SEC), 10% margin |
| Efficiency | Mixed — ROE 10%, ROA 7.1% (last 4 quarters, SEC) |
Ownership (VMD)
| Insider Ownership | +13.93% |
|---|---|
| Institutional Ownership | +70.92% |
| Shares Outstanding | 38.09M |
| Float | 30.64M |
| Short % of Float | +4.68% |
Source: Nexqual, October 29, 2026 at 11:03 UTC.
Leadership (VMD)
Viemed Healthcare, Inc. is led by Casey Hoyt, CEO & Director, per Nexqual as of October 29, 2026 at 11:03 UTC.
| CEO & Director | Casey Hoyt |
|---|---|
| President | Michael B. Moore CRT |
| Chief Financial Officer | Trae Paul Fitzgerald |
| COO & Director | William Todd Zehnder |
| Chief Medical Officer & Director | William Dana Frazier |
Major Backers & Investors (VMD)
Notable institutional backers of Viemed Healthcare, Inc. include Forager Capital Management, LLC, Goldman Sachs, Ameriprise Financial, Inc., according to Nexqual as of October 29, 2026 at 11:03 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Forager Capital Management, LLC | 5.62% |
| Goldman Sachs | 3.21% |
| Ameriprise Financial, Inc. | 2.64% |
| Arrowstreet Capital, Limited Partnership | 2.06% |
| Nantahala Capital Management, LLC | 1.66% |
| Fidelity | 1.58% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.57% |
| Vanguard Group | 3.47% |
| Geode Capital | 2.56% |
| State Street | 2% |
Source: Nexqual, October 29, 2026 at 11:03 UTC.
Legal & Regulatory Risks from Viemed Healthcare, Inc.'s Latest 10-K (filed 2026-03-04)
- We are subject to extensive federal and state regulation, and if we fail to comply with applicable regulations, we could suffer severe criminal or civil sanctions or be required to make significant changes to our operations that could adversely affect our business, financial condition and operating results.
- We expect the federal and state governments to continue their efforts to contain growth in Medicaid expenditures, which could adversely affect our revenue and profitability.
- We face inspections, reviews, audits and investigations under federal and state government programs and contracts. These audits could have adverse findings that may negatively affect our business.
- We are subject to extensive federal and state laws and regulations relating to the privacy and security of protected health information and failure to comply with such laws may increase our operational costs.
Source: SEC EDGAR 10-K, Item 1A, official filing.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| INSP | Inspire Medical Systems, Inc. | USD 70.97 | ▼ 0.46% |
| ESTA | Establishment Labs Holdings Inc | USD 68.97 | ▲ 3.02% |
| BFLY | Butterfly Network, Inc. | USD 7.81 | ▲ 5.83% |
| UFPT | UFP Technologies, Inc. | USD 286 | ▼ 3% |
| TMDX | TransMedics Group, Inc. | USD 66.9 | ▼ 4.06% |
| ALMR | Alamar Biosciences, Inc. | USD 34.3 | ▲ 7.42% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 11:03 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt